- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03447379
Short-term Dual Antiplatelet Therapy After Deployment of Bioabsorbable Polymer Everolimus-eluting Stent
September 14, 2022 updated by: Bumkee Hong, Gangnam Severance Hospital
To compare the clinical outcomes of P2Y12 antagonist monotherapy with aspirin plus P2Y12 antagonist following 3-month of DAPT in patients undergoing PCI with bioabsorbable polymer Everolimus-eluting stents (Synergy®)
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
1452
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Souel
-
Seoul, Souel, Korea, Republic of
- Gangnam Severance Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
19 years to 85 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Age 19+
- Patients treated with a new generation of Evelorimus-eluting stents (Synergy®)
- Patients who understand the content of the subject description and voluntarily sign the subject
Exclusion Criteria:
- Age 86+
- Hemodynamically unstable patient
- Severe hypersensitivity reactions to aspirin, clopidogrel, ticagrelor, everolimus, contrast agent
- Patients at high risk of bleeding, anemia, thrombocytopenia
- Patients requiring oral anticoagulants
- Pregnant women or women of childbearing age
- Life expectancy is less than one year
- Patients receiving a potent CYP3A4 inhibitor (eg, ketoconazole, clarithromycin, napjodone, ritonavir, atazanavir)
- Patients with a history of intracranial hemorrhage
- Patients with moderate to severe hepatic impairment
- Patients underwent coronary intervention with stenting within 1 year
- Patients with left-main lesions requiring coronary intervention
- Patients with chronic stricture lesions requiring treatment
- Patients with in-stent restenosis in a lesion requiring treatment
- Patients with bifurcation lesions requiring stenting in lateral branches
- Patients with lesions requiring more than 3 stents
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: P2Y12 antagonist monotherapy
P2Y12 antagonist monotherapy after 3-month DAPT
|
P2Y12 inhibitor(Clopidogrel 75mg/day or Ticagrelor 180mg/day) for 9months after 3 months of DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day)
|
Active Comparator: Aspirin + P2Y12 antagonist
Aspirin + P2Y12 antagonist after 3-month DAPT
|
DAPT(Aspirin 100mg/day + Clopidogrel 75mg/day or Aspirin 100mg/day + Ticagrelor 180mg/day) for a year
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Major adverse cardiovascular clinical events (MACCE)
Time Frame: between 3 and 12 month after the procedure
|
cardiovascular-related death, myocardial infarction, stent thrombosis, stroke, or target lesion revascularization
|
between 3 and 12 month after the procedure
|
Major bleeding
Time Frame: between 3 and 12 month after the procedure
|
The Bleeding Academic Research Consortium (BARC) type 3 or 5
|
between 3 and 12 month after the procedure
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Bumkee Hong, Gangnam Severance Hospital
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 15, 2017
Primary Completion (Actual)
August 17, 2022
Study Completion (Anticipated)
October 31, 2022
Study Registration Dates
First Submitted
December 1, 2017
First Submitted That Met QC Criteria
February 26, 2018
First Posted (Actual)
February 27, 2018
Study Record Updates
Last Update Posted (Actual)
September 15, 2022
Last Update Submitted That Met QC Criteria
September 14, 2022
Last Verified
September 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Arteriosclerosis
- Arterial Occlusive Diseases
- Coronary Disease
- Coronary Artery Disease
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Fibrinolytic Agents
- Fibrin Modulating Agents
- Platelet Aggregation Inhibitors
- Cyclooxygenase Inhibitors
- Antipyretics
- Aspirin
Other Study ID Numbers
- 3-2017-0230
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Coronary Artery Disease
-
Elixir Medical CorporationIstituto Clinico HumanitasActive, not recruitingCoronary Artery Disease | Chronic Total Occlusion of Coronary Artery | Multi Vessel Coronary Artery Disease | Bifurcation of Coronary Artery | Long Lesions Coronary Artery DiseaseItaly
-
Fundación EPICActive, not recruitingCoronary Artery Disease | Left Main Coronary Artery Disease | Left Main Coronary Artery Stenosis | Restenosis, CoronarySpain
-
Peking Union Medical College HospitalNot yet recruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
Peking Union Medical College HospitalRecruitingCoronary Artery Disease | Inflammation | Coronary Artery Disease Progression | Coronary Artery Stenosis | Coronary Artery Restenosis | Inflammatory Disease | Inflammation VascularChina
-
IGLESIAS Juan FernandoUniversity of BernNot yet recruiting
-
National Institutes of Health Clinical Center (CC)National Heart, Lung, and Blood Institute (NHLBI)CompletedCoronary Arteriosclerosis | Coronary Artery Disease (CAD) | Obstructive Coronary Artery DiseaseUnited States
-
Barts & The London NHS TrustImperial College London; Brunel UniversityNot yet recruitingCORONARY ARTERY DISEASE
-
Fundación EPICRecruitingCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Left Main Coronary Artery Disease | Coronary Artery StenosisSpain
-
Abbott Medical DevicesCompletedCoronary Artery Disease | Coronary Disease | Coronary Occlusion | Chronic Total Occlusion of Coronary Artery | Coronary Restenosis | Coronary Artery Stenosis | Coronary Artery RestenosisBelgium
-
China National Center for Cardiovascular DiseasesRecruitingLeft Main Coronary Artery DiseaseChina
Clinical Trials on P2Y12 antagonist monotherapy
-
Samsung Medical CenterUnknownCoronary Artery DiseaseKorea, Republic of
-
Feng Yuan Hospital, Ministry of Health and WelfareCheng-Hsin General HospitalRecruitingHemorrhage | Acute Coronary Syndrome | Treatment Side EffectsTaiwan
-
Italian Society of Invasive CardiologyEustrategyUnknownAcute Coronary Syndrome | Coronary AngioplastyItaly
-
Beijing Anzhen HospitalUnknownPercutaneous Coronary InterventionChina
-
University of California, San FranciscoNot yet recruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
Masonic Cancer Center, University of MinnesotaActive, not recruiting
-
Xizang Haisco Pharmaceutical Co., LtdRecruiting
-
Peking Union Medical College HospitalCompletedChronic Periaortitis | Tocilizumab MonotherapyChina
-
Azienda Ospedaliera Universitaria Policlinico "G...Gianluca Di Bella; Antonio Micari; Giampiero Vizzari; Giorgio Quadri; Greca Zanda; Ferdinando...RecruitingCoronary Artery Disease | Acute Coronary Syndrome | Dual Antiplatelet TherapyItaly
-
PharmAbcineC&R Research, Inc.RecruitingNeovascular Age-related Macular DegenerationKorea, Republic of